PUBLISHER: The Business Research Company | PRODUCT CODE: 1760464
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760464
Aripiprazole is an antipsychotic drug that functions as a partial agonist at dopamine D2 and serotonin 5-hydroxytryptamine receptor 1A (5-HT1A) receptors, and as an antagonist at serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptors. It is primarily prescribed for the treatment of schizophrenia, bipolar disorder, and as an adjunct therapy for major depressive disorder. By modulating dopamine and serotonin levels in the brain, it helps alleviate symptoms such as hallucinations, delusions, and mood fluctuations.
The primary indications for aripiprazole include schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorder. Schizophrenia is a long-term mental health condition characterized by hallucinations, delusions, and disorganized thinking, and aripiprazole aids in symptom control by balancing dopamine and serotonin activity in the brain. The medication is prescribed across a range of patient groups, including pediatric, adult, and geriatric populations. It is available in various dosage forms such as oral tablets, oral solutions, and injectable formulations, and is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The aripiprazole market research report is one of a series of new reports from The Business Research Company that provides aripiprazole market statistics, including aripiprazole industry global market size, regional shares, competitors with an aripiprazole market share, detailed aripiprazole market segments, market trends and opportunities, and any further data you may need to thrive in the aripiprazole industry. The aripiprazole market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The aripiprazole market size has grown strongly in recent years. It will grow from $7.04 billion in 2024 to $7.65 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth during the historic period can be attributed to the increasing prevalence of schizophrenia and bipolar disorders, heightened awareness of mental health issues, expanded off-label use of aripiprazole, a growing geriatric population, and rising healthcare spending.
The aripiprazole market size is expected to see strong growth in the next few years. It will grow to $10.53 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period is expected to be driven by the rising incidence of depression and anxiety disorders, a stronger emphasis on personalized medicine, broader acceptance of generic aripiprazole, increased investment in psychiatric drug research, and the expansion of telepsychiatry and digital health platforms. Key trends projected for the forecast period include the development of long-acting injectable formulations, progress in nanoparticle-based drug delivery systems, incorporation of digital tools for adherence monitoring, the use of artificial intelligence in drug discovery, and the integration of telemedicine for prescribing and monitoring.
The rising incidence of psychiatric disorders is anticipated to drive the growth of the aripiprazole market in the future. Psychiatric disorders encompass a variety of mental health conditions that influence an individual's thoughts, emotions, behaviors, and daily functioning. Factors such as chronic stress, social isolation, and the pressures of modern lifestyles are contributing to the increasing rates of these disorders. Aripiprazole supports the treatment of psychiatric conditions by regulating dopamine and serotonin activity in the brain, making it effective for managing schizophrenia, bipolar disorder, and major depressive disorder. It offers improved symptom control through flexible dosing options, promoting better treatment adherence and enhancing patients' overall quality of life. For example, in 2022, the National Institute of Mental Health, a U.S.-based federal research agency, reported that 59.3 million adults aged 18 and older in the United States experienced any mental illness (AMI), representing 23.1% of the adult population. Consequently, the growing prevalence of psychiatric disorders is fueling the expansion of the aripiprazole market.
An increase in healthcare expenditure is also expected to contribute to the growth of the aripiprazole market. Healthcare expenditure includes the total financial resources allocated to medical services, treatments, healthcare infrastructure, research, and public health efforts aimed at enhancing overall health outcomes. The rising need for healthcare spending stems from the growing burden of chronic mental health conditions, which necessitate continuous treatment, medication, and long-term care strategies. Increased healthcare funding supports the broader adoption of aripiprazole by improving access to advanced treatment options, ensuring a stable supply of medication, and enhancing the quality of patient care. It also bolsters healthcare systems by financing prolonged therapeutic programs, leading to improved outcomes for individuals with psychiatric conditions. For instance, in December 2024, the Centers for Medicare and Medicaid Services (CMS), a U.S.-based federal agency, stated that national health expenditures grew by 7.5% to $4.9 trillion in 2023, making up 17.6% of the gross domestic product (GDP). Moreover, from 2023 to 2032, average annual health expenditure is projected to increase by 5.6%, with healthcare spending expected to rise from 17.3% of GDP in 2022 to 19.7% in 2032. Thus, the growth in healthcare expenditure is driving the aripiprazole market forward.
Leading players in the aripiprazole market are focusing on innovation and securing regulatory approvals, such as product line extensions, to improve patient adherence, expand treatment applications, and retain market share after patent expirations. Product line extension involves introducing new variations of an existing product within the same brand, typically by modifying the formulation, dosage, packaging, or delivery method to meet evolving patient needs or broaden the product's reach, while maintaining the original compound. For instance, in September 2022, Otsuka Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, along with Lundbeck, a Denmark-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) acceptance for their New Drug Application (NDA) for a 2-month, ready-to-use, long-acting injectable formulation of aripiprazole. This treatment is intended for adults with schizophrenia and for maintenance monotherapy in bipolar I disorder. The formulation delivers a steady release of aripiprazole over time, enabling patients to receive treatment once every two months.
Major players in the aripiprazole market are Novartis AG, Teva Pharmaceutical Industries Ltd., Hetero Drugs, Sun Pharmaceutical Industries Ltd., Cipla Limited, Zydus Lifesciences, Neuland Laboratories Ltd., Ipca Laboratories Limited, Jubilant Pharmova, MSN Laboratories Pvt. Ltd., Harman Finochem Ltd., SMS Pharmaceuticals, Erregierre S.p.A., Tiefenbacher API + Ingredients GmbH & Co. KG, Alkem Laboratories Ltd., Suraj Laboratories Pvt. Ltd, Octavius Pharma Pvt. Ltd., Tooba Pharmaceuticals Private Limited, Senores Pharmaceuticals Pvt. Ltd., and Gonane Pharma.
North America was the largest region in the aripiprazole market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in aripiprazole report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the aripiprazole market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The aripiprazole market consists of sales of oral tablets, orally disintegrating tablets, and long-acting injectable suspensions. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Aripiprazole Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on aripiprazole market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for aripiprazole ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The aripiprazole market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.